Article Text
Abstract
The National Institute for Health and Clinical Excellence has recently published an update of technology appraisal guidance 90, first published in 2005, which evaluated the use of clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events. This article considers the update in detail and discusses the implications for clinical practice.
- Antiplatelet treatment
- platelets
Statistics from Altmetric.com
Footnotes
Competing interests Dr Dawson has previously received speaker honoraria for lectures on anti-platelet therapy from Sanofi-Aventis and Bristol Myers Squibb.
Provenance and peer review Commissioned; externally peer reviewed.
Request Permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.